Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled …

M Martin, FA Holmes, B Ejlertsen, S Delaloge… - The lancet …, 2017 - thelancet.com
Background ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine
kinase inhibitor, significantly improves 2-year invasive disease-free survival after …
被引用次数：649 相关文章

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled …

M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy… - The Lancet …, 2017 - Elsevier
Background ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine
kinase inhibitor, significantly improves 2-year invasive disease-free survival after …

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled …

ExteNET Study Group - The Lancet Oncology, 2017 - profiles.wustl.edu
Background ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine
kinase inhibitor, significantly improves 2-year invasive disease-free survival after …

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled …

ExteNET Study Group - The Lancet Oncology, 2017 - utsouthwestern.elsevierpure.com
Background ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine
kinase inhibitor, significantly improves 2-year invasive disease-free survival after …

[引用][C] Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo …

M Martin, F Holmes, B Ejlertsen… - THE LANCET …, 2017 - iris.unicampus.it

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled …

M Martin, FA Holmes, B Ejlertsen… - The Lancet …, 2017 - eprints.whiterose.ac.uk
Background: ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine
kinase inhibitor, significantly improves 2-year invasive disease-free survival after …

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled …

M Martin, M Gnant, Z Tomašević, N Denduluri… - Lancet oncology, 2017 - croris.hr
BACKGROUND: ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine
kinase inhibitor, significantly improves 2-year invasive disease-free survival after …

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled …

SA Im, ExteNET Study Group - The Lancet Oncology, 2017 - s-space.snu.ac.kr
© 2017 Elsevier LtdBackground ExteNET showed that 1 year of neratinib, an irreversible
pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free …

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled …

ExteNET Study Group - The Lancet Oncology, 2017 - portal.findresearcher.sdu.dk
Background ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine
kinase inhibitor, significantly improves 2-year invasive disease-free survival after …

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled …

M Martin, FA Holmes, B Ejlertsen, S Delaloge… - Lancet …, 2017 - research.regionh.dk
BACKGROUND: ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine
kinase inhibitor, significantly improves 2-year invasive disease-free survival after …